Table 4 Changes of regional myocardial function (VM202 injected area)
From: Intramyocardial transfer of hepatocyte growth factor as an adjunct to CABG: phase I clinical study
Modality | Parameter | Months after VM202 treatment | Measurement | P-valuea | Adjusted P-valuea | |
|---|---|---|---|---|---|---|
Mean±s.d. | Median (range) | |||||
Myocardial SPECT | Stress perfusion (%) | Baseline | 58.3±10.2 | 60.0 (41.5∼69.5) | 0.0031 | — |
3 | 64.3±9.6 | 69.0 (51.0∼74.5) | 0.024 | |||
6 | 63.9±9.7 | 68.0 (47.5∼76.5) | 0.024 | |||
Rest perfusion (%) | Baseline | 70.2±8.6 | 72.5 (51.0∼81.0) | 0.0705 | — | |
3 | 74.5±7.5 | 74.5 (61.0∼84.5) | — | |||
6 | 72.2±7.9 | 72.0 (61.5∼89.5) | — | |||
Systolic thickening (%) | Baseline | 33.4±22.8 | 42.5 (0.0∼70.5) | 0.7479 | — | |
3 | 32.4±11.3 | 35.5 (17.0∼55.5) | — | |||
6 | 34.2±14.5 | 36.0 (12.0∼51.0) | — | |||
Cardiac MRI | Systolic wall thickness (mm) | Baseline | 10.3±2.8 | 10.0 (6.5∼15.0) | 0.0650 | — |
3 | 10.8±2.6 | 11.0 (6.1∼15.3) | — | |||
6 | 11.0±2.4 | 11.5 (6.3∼13.9) | — | |||
Diastolic wall thickness (mm) | Baseline | 7.0±1.0 | 7.0 (5.5∼8.7) | 0.0731 | — | |
3 | 7.5±1.2 | 7.7 (5.4∼9.2) | — | |||
6 | 7.5±1.1 | 7.8 (5.1∼9.0) | — | |||
Systolic thickening (%) | Baseline | 46.1±26.6 | 43.0 (15.0∼89.0) | 0.6544 | — | |
3 | 42.8±22.7 | 53.0 (12.0∼68.0) | — | |||
6 | 46.6±17.4 | 55.0 (19.0∼64.0) | — | |||
